Site Map | Malaria FAQ | Info Request | Donate for Malaria | RBM Partnership Newsletter
Home
The RBM Partnership Global malaria advocacy Country action Commodity Services Publications and multimedia

Eritrea: Progress and Challenges towards SUFI

Malaria Prevalence Distribution - Eritrea

Malaria interventions coverage

Indicator 2002 2005
% pregnant women sleeping under insecticide-treated mosquito nets 3 50
% children with fever receiving any anti-malarial medicines 4 -
% children with fever receiving any anti-malarial medicines promptly (within 24 hours) 2 -
% children with fever receiving any anti-malarial medicines 4 -
% children sleeping under insecticide-treated mosquito nets 4 59
% children sleeping under any type of mosquito net 12 -
Household availability of at least one mosquito net of any type (%) 34 -

Source of the data: DHS 2002; NMCP

I. Epidemiological background

Parasite (Plasmodium) types The main parasites are Plasmodium falciparum and Plasmodium Vivax. The parasite distribution (2005) was P.falciparum (83%) and P.vivax (17%).
Main vector (mosquito) types The vector is almost exclusively Anopheles arabiensis.
Total population 3,990,36 (2006)
Population at risk 2,673,546 (2006)
67% of the Population lives in areas at risk of malaria: 41 out of the 58 sub-zonas (Sub-regions).
Transmission Malaria transmission in Eritrea is highly seasonal and unstable: There are two main malaria transmission seasons: September – November (for central, southern, western lowlands) and January – March (for the coastal plains). In brief, malaria is seasonal, focal, and unstable with a risk for malaria epidemics.
Women aged between 15-45 years of age at risk of malaria 528,900 (2006)
Children under five at risk of malaria 432,000 (2006)
Number of reported clinical malaria / fever cases 14,148 (2006)
Child under 5 malaria mortality 9 (2006)
Infant mortality (per 1000) 50 (2005)

Source of the data: WHO statistics 2007

II. Current Policy and Strategy

Primary interventions: Policy

Case management
  • 1st line treatment for uncomplicated falciparum malaria is Artesunate + Amodiaquine (AS+AQ).
  • The 2nd treatment for treatment failures is oral Quinine.
  • The treatment for severe malaria is parenteral Quinine.
  • Treatment of malaria during the pregnancy is Quinine in all trimesters but AS+AQ might be considered when Quinine is not available and when the benefit outweighs the risk.
  • The treatment of malaria in areas where confirmation of malaria either by microscopy or RDTs is NOT possible is CQ+SP.
Prevention
  • The use of ITNs, Larviciding, Indoor residual spraying in selected villages
  • Malaria prevention during the pregnancy:
    ITNs are provided freely by the health facilities to all the pregnant women who attend ANC during their 1st clinic visit and also during and after delivery.
Primary interventions: Strategy
  • Case Management
    Early detection and prompt treatment
  • Integrated Vector Management:
    (Environmental Management, Use of ITNs, Larviciding, Indoor residual spraying in selected villages)
  • Epidemic Prevention
    (forecasting, monitoring of sentinel sites, preparedness)
  • Capacity Building
    (Training of Health workers, Community Health Agents, Public Health Technicians etc.)
  • Health Promotion
  • Operational Research
  • Monitoring and Evaluation
III. Primary interventions

[+] ITNs

[+] Indoor residual spraying (IRS)

[+] Malaria IPD

[+] View data

IV. Challenges and Priority support needs (2008 - 2010)

Challenges

The significant reduction of malaria morbidity creates other challenging issues/factors:

  • low immunity of population, tendency to develop severe malaria and prone to malaria epidemics;
  • challenge of sustaining the achievements and successes obtained;
  • creates complacence/relaxation among population, MOH, Partners among others;
  • generally limited infrastructure (transport, laboratory, communications);
  • generally limited trained human resources in the General Health Delivery System;
  • generally limited data base for linking epidemiological, entomological, ecological, and climate-related data to predict epidemics;
  • general concern of sustaining community based interventions (bednet issues, source reduction, case management) ownership and support for community health agents (CHAs) incentives;
  • cross-border malaria concern.

Support needs (TA and Finance)

  • Updating of AMDs Policy, dissemination and training of HWs and CHAs;
  • Procurement of adequate AMDs (ACTs);
  • Procurement of adequate RDTs;
  • Procurement of LLINs, insecticides etc;
  • Improve the early treatment seeking behavior and use of ITNs of the population and particularly of the vulnerable groups (<5, pregnant women, the military & other non immune population) by conducting aggressive HP/BCC activities;
  • Goluj Project and Construction of ware house in Gash Barka (which has already eaten too much time).
V. Key RBM Partners in Ertrea

  • National Government Contribution – big and continuous
  • GFATM – The second biggest financial support since the end of 2003
  • Local associations/NGOs, ministries, communities – big & continuous
  • WHO - Technical & Financial since 1995
  • UNICEF – Technical & Financial since 1995
  • IDA/World Bank – Big Financial & technical support since 1998
  • Italian Cooperation/PHARPE – Financial support since 1997
  • JICA: Japan International Cooperation Agency – Material support (c. 30,000 LLINs/yr.) since 2003/4

Source: NMCP Eritrea

For questions, contact Ms Nadia Lasri, RBM Partnership facilitation
Dr J. Banda, RBM Partnership facilitation Coordinator,
Dr Tewolde Ghebremeskel , National Malaria Control Programme Manager

RESOURCES & LINKS:

Eritrean Roll Back Malaria Program Five Year Strategic Plan 2005-2009

Five Year (2005-2009) Plan of Action

Malaria treatment protocols:
WHO Global AMDP database

Malaria contry profiles
World Malaria report 2005
WHO/AFRO

Online publications:
PubMed

Maps:
MARA/ARMA Eritrea maps

Valid XHTML 1.0 Strict